Because it has low cytotoxicity toward cells, T638 can be combined with other cancer drugs to increase the level of tumor suppression with minimum doses, making it a suitable candidate for combination therapy with DNA repair inhibitors without the side effects associated with high doses of Top2 poisons. The gene discussed is TOP2A; the disease is neoplasm.